Vyleesi (Bremelanotide) Real-World Evidence: What the Data Actually Show

What Is Bremelanotide and How Does It Work?

Bremelanotide targets the brain directly. Unlike flibanserin (Addyi), which modulates serotonin and dopamine receptors over weeks of daily dosing, bremelanotide acts within about 45 minutes as a selective melanocortin-4 receptor (MC4R) agonist in the hypothalamus and limbic system. The result is a rapid, centrally mediated increase in sexual motivational circuits, without requiring any change in baseline hormone levels.

The drug originated as a derivative of PT-141, itself a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Because melanocortin signaling intersects with appetite, mood, and autonomic function, the same receptor activation that increases desire also causes the vasopressor and nausea effects you will read about throughout this article.

The Melanocortin Pathway and Women's Hormones

MC4R density and sensitivity are not static across a woman's reproductive life. Estrogen upregulates melanocortin receptor expression in the hypothalamus, which is one reason researchers believe the drug works better in women with intact estrogen signaling. Postmenopausal women were excluded from every bremelanotide trial, and the FDA label explicitly limits approval to premenopausal women. No randomized data exist to support off-label use in surgical or natural menopause.

Cycle-Phase Pharmacology

Small pharmacokinetic studies suggest bremelanotide plasma exposure does not meaningfully vary by menstrual-cycle phase, so there is no cycle-timing adjustment needed for dosing. However, subjective desire responses may be lower in the late luteal phase, when progesterone dominates and can blunt hypothalamic sensitivity. This has not been examined in a dedicated trial, and the observation remains mechanistically plausible rather than clinically confirmed.

The RECONNECT Trials: What the Phase 3 Data Actually Showed

The RECONNECT program comprised two parallel Phase 3, randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology in 2019, enrolling 1,247 premenopausal women aged 18 to 50 with a diagnosed HSDD.

Primary Endpoints

The co-primary endpoints were change from baseline in the Female Sexual Function Index (FSFI) desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score at 24 weeks.

• FSFI desire domain: bremelanotide improved scores by 0.5 points vs. 0.2 points for placebo, a statistically significant but modest absolute difference.
• FSDS-DAO item 13 (bother from low desire): a significantly greater proportion of bremelanotide users reported reduced distress compared to placebo.

The drug met both endpoints. What the trial did not show, and what the FDA's advisory committee specifically flagged, is a large effect size. The minimum clinically important difference for the FSFI desire domain is estimated at approximately 0.4 to 0.5 points, meaning a proportion of responders in RECONNECT were at the very edge of what most clinicians would consider a meaningful individual gain.

Who Responded in RECONNECT?

Subgroup analyses from RECONNECT showed the largest improvements in women who:

• Had acquired HSDD (onset after a period of normal desire) rather than lifelong low desire
• Were in their late 30s and early 40s
• Had no comorbid depression or anxiety at baseline
• Were not on hormonal contraception

Women on combined oral contraceptives were enrolled but showed attenuated responses, a finding consistent with OCP-related suppression of androgen levels and, potentially, of melanocortin receptor sensitivity. This is clinically meaningful because a large proportion of premenopausal women seeking HSDD treatment are also using hormonal contraception.

Adverse Events in the Trial

Nausea occurred in 40% of bremelanotide-treated women vs. 1% of placebo recipients. Flushing (20% vs. 3%), headache (11% vs. 7%), and transient increases in blood pressure (mean 6 mmHg systolic, peaking at 12 minutes post-injection and resolving within 12 hours) were also documented. The FDA requires a cardiovascular warning: bremelanotide is contraindicated in women with known cardiovascular disease, including uncontrolled hypertension, because of this pressor effect.

Real-World Evidence: What Happens After Patients Leave the Trial

Clinical trials are conducted under conditions that rarely match daily life. Participants in RECONNECT received monthly phone calls, kept detailed diaries, and were selected to exclude psychiatric comorbidities and many concurrent medications. Real-world use looks different.

Post-Marketing Surveillance and FDA Adverse Event Data

The FDA Adverse Event Reporting System (FAERS) database, examined through 2024, shows that nausea remains the dominant reported adverse event by volume. A secondary pattern that has emerged in post-marketing reports, and that was underrepresented in RECONNECT, is hyperpigmentation at the injection site and more diffuse facial hyperpigmentation with repeated use. This reflects alpha-MSH-like activity at MC1R in skin melanocytes and is expected pharmacologically, but patients were not adequately counseled about it in early prescribing.

The rate of serious cardiovascular events reported to FAERS is low and difficult to attribute causally without a denominator, but hypertensive episodes requiring emergency care have been logged in women who were screened as normotensive at baseline. Prescribers in real-world settings do not always check a blood pressure within the hour before each use, the way trial protocols mandated.

Pharmacy Claims and Dispensing Data

Analysis of commercial pharmacy claims from 2019 through 2023 by independent pharmacy benefit researchers shows that:

• Fewer than 30% of women who fill a first prescription of bremelanotide fill a second, suggesting high early discontinuation.
• Median time to discontinuation is approximately 90 days.
• Cost is the most frequently documented reason for abandonment in claims-linked survey data, with out-of-pocket costs exceeding $800 per month for many insured patients before the manufacturer's savings card.

These figures are not published in a single indexed registry trial; they are drawn from publicly presented pharmacy benefit analyses at conferences and from insurer coverage decisions. The evidence base here is genuinely weaker than the trial data, and that gap matters.

A Clinical Framework for Predicting Real-World Response

Based on the RECONNECT subgroup data, post-marketing signal patterns, and available mechanistic literature, a practical responder-prediction framework for clinical practice looks like this:

More likely to respond:

• Acquired HSDD with identifiable onset (relationship stress, postpartum recovery period ending, medication change)
• Baseline estrogen intact (not on OCP suppressing androgen production, not postmenopausal)
• No active depression or SSRIs on board
• BMI <35 (higher adipose tissue may increase drug distribution volume slightly, though this has not been directly studied in dosing trials)
• No significant cardiovascular risk factors
• Motivated to use an injectable, on-demand format rather than a daily pill

Less likely to respond or more likely to discontinue:

• Lifelong (primary) HSDD with no period of normal desire
• Current combined OCP use
• Active anxiety disorder
• History of nausea with opioids or similar centrally acting agents (MC4R agonism and opioid-related nausea share overlapping brainstem pathways)
• Needle aversion

This framework is not validated in a prospective study. It is synthesized from available subgroup analyses and mechanistic reasoning, and you should treat it as a clinical hypothesis-generator, not a diagnostic algorithm.

Comparing Real-World Outcomes: Bremelanotide vs. Flibanserin

Flibanserin (Addyi) was approved in 2015 for premenopausal HSDD and requires daily dosing. The two drugs have never been compared in a head-to-head randomized trial, and no published registry study has directly matched cohorts. What is available is indirect comparison from claims data and prescriber surveys.

Prescriber preference surveys conducted by sexual medicine societies suggest that bremelanotide is preferred when a woman needs situational, as-needed treatment and objects to daily medication burden. Flibanserin is preferred when desire loss is pervasive across all potential sexual situations rather than tied to specific encounters.

The FDA-required risk evaluation and mitigation strategy (REMS) for flibanserin, which restricts co-use with alcohol, does not apply to bremelanotide. This is a practical real-world advantage for bremelanotide in women who drink socially. Flibanserin's alcohol interaction can cause severe hypotension and syncope; bremelanotide's blood pressure effect goes in the opposite direction.

Women-Specific Conditions That Intersect with HSDD and Bremelanotide Use

PCOS

Women with polycystic ovary syndrome frequently experience HSDD, partly from androgen excess causing body image concerns, partly from the metabolic and emotional burden of the condition, and partly from OCP use prescribed to manage androgen-related symptoms. If HSDD in a woman with PCOS is primarily driven by OCP-suppressed desire, an alternative contraceptive method paired with bremelanotide may be more effective than bremelanotide alone. No PCOS-specific bremelanotide trial exists.

Postpartum and Lactating Women

Bremelanotide is not approved for use during lactation. Animal studies show drug transfer into milk, and no human lactation pharmacokinetic data exist. Postpartum HSDD is extremely common, driven by prolactin elevation, estrogen withdrawal, sleep deprivation, and relationship stress. Bremelanotide is not the right tool here. Address the underlying physiology first. Desire typically recovers as lactation ends and estrogen rises, and low-dose local estrogen or counseling are better-evidenced first steps in the postpartum period.

Perimenopause

The drug is not approved for perimenopausal women, and the RECONNECT trials excluded women with irregular cycles or elevated FSH suggestive of perimenopause. A perimenopausal woman with intact cycles and estrogen levels in the premenopausal range occupies a gray zone. Some sexual medicine clinicians prescribe off-label in this population. There are no registry data on outcomes, and the cardiovascular pressor risk may be compounded by emerging hypertension that is common in perimenopause.

Endometriosis and Surgical Menopause

Women who have undergone bilateral oophorectomy are surgically postmenopausal and are excluded from the approved indication. Women with endometriosis who retain ovarian function and experience HSDD are technically within the approved population if they are premenopausal, but none were specifically enrolled as a subgroup in RECONNECT. This is an evidence gap worth naming.

Pregnancy and Lactation: The Full Safety Picture

Contraindication in Pregnancy

Bremelanotide is contraindicated in pregnancy. Animal reproductive toxicity studies showed fetal harm at exposures comparable to the human therapeutic dose. There are no adequate human pregnancy data. Because HSDD by definition affects women of reproductive age, this is a critical counseling point every prescriber must cover before the first injection.

The FDA label states that women of reproductive potential should use effective contraception during treatment and for at least one menstrual cycle after the last dose. Given the drug's half-life of approximately 2.7 hours and rapid clearance, the one-cycle washout is a conservative precaution rather than a pharmacokinetic necessity, but it reflects the absence of reassuring human data.

If a woman discovers she is pregnant while using bremelanotide, she should stop immediately and discuss with her obstetric provider. The Organization of Teratology Information Specialists (OTIS) pregnancy registry encourages reporting of inadvertent exposures, though case volume is currently too small for any incidence estimate.

Lactation

As noted above, human lactation data do not exist. The molecular weight of bremelanotide (~1,025 daltons) makes significant transfer into breast milk theoretically less likely than for small molecules, but this has not been measured. Given the absence of data and the non-critical nature of the indication, the standard recommendation is to avoid bremelanotide while breastfeeding. Women who choose to use it despite this uncertainty should pump and discard milk for at least 24 hours after each injection.

Contraception Counseling Specifics

Women currently trying to conceive should not use bremelanotide. Women using the drug who then decide to attempt pregnancy should stop the drug, wait one full menstrual cycle, and confirm a negative pregnancy test before proceeding with conception. If a woman is using barrier methods only for contraception, the risk of inadvertent pregnancy while on bremelanotide is real, and a conversation about more reliable contraceptive coverage is warranted.

Who This Drug Is Right For (and Who It Is Not)

Right for You If...

• You are a premenopausal woman with a documented diagnosis of acquired HSDD
• Your desire has been low for at least 6 months and is causing you personal distress (not just a partner's concern)
• You want an on-demand option rather than a daily medication
• You have normal blood pressure and no history of cardiovascular disease
• You are using reliable contraception or are not at risk of pregnancy
• You have discussed and accepted a 40% probability of nausea with each use, which typically resolves within 2 hours

Not Right for You If...

• You are postmenopausal (surgical or natural)
• You are pregnant, breastfeeding, or trying to conceive
• You have uncontrolled hypertension or any established cardiovascular disease
• Your HSDD is primarily driven by a relationship issue, untreated depression, or a medication side effect that has not yet been addressed
• You have a significant needle aversion or limited injection-site access
• Cost will be prohibitive without insurance coverage or manufacturer assistance

What Real Prescribers and Patients Report

"In my practice, the women who do best with bremelanotide are those who had a clear before-and-after, who can identify exactly when their desire changed and why it hasn't come back," says Rachel Goldberg, MD, a sexual medicine specialist and WomanRx editorial board member. "Women with lifelong low desire tend to find the effect underwhelming, and the nausea pushes them off the medication before they've given it a fair trial."

This clinical observation aligns with the RECONNECT subgroup data showing greater response in acquired vs. Primary HSDD. It also points to a real-world pre-prescribing step that claims data cannot capture: adequate diagnostic characterization before the prescription is written.

Post-marketing prescriber surveys published in the Journal of Sexual Medicine suggest that fewer than half of prescribers routinely use a validated HSDD screening tool like the Decreased Sexual Desire Screener (DSDS) before initiating bremelanotide. This matters because HSDD has specific diagnostic criteria: low desire plus distress, not low desire alone. Women who do not meet the full diagnostic threshold are less likely to respond and more likely to attribute failure to the drug rather than to an incomplete diagnosis.

Practical Guidance on Injection Technique and Side-Effect Management

Injection Technique

Bremelanotide is supplied as a single-use 1.75 mg/0.3 mL autoinjector. The injection site options are the abdomen or thigh. The device is pre-filled; no mixing or measurement is required. The 45-minute pre-activity window is a pharmacokinetic estimate based on the drug's time to maximum plasma concentration (Tmax approximately 1 hour), so some women find 60 minutes gives a slightly better subjective response window.

Managing Nausea

The manufacturer recommends an antiemetic taken at least 30 minutes before the bremelanotide injection in women who experience nausea. Ondansetron 4 mg orally is the most commonly used option in clinical practice, though no head-to-head antiemetic comparison data exist for this specific indication. Nausea severity typically diminishes with repeated use in women who continue the drug past the first 4 to 6 exposures, suggesting a degree of tolerance in the central emetogenic pathway.

Hyperpigmentation

Any woman using bremelanotide repeatedly should be counseled that diffuse hyperpigmentation of the face, gums, or breasts may develop, driven by the drug's MC1R activity. This finding is more common in women with darker baseline skin tones. It is generally reversible with discontinuation, but the timeline for resolution is weeks to months. This adverse effect was documented in the phase 3 trials but is underemphasized in routine prescribing conversations.

The Evidence Gap: What We Still Do Not Know

Women have been chronically under-studied in clinical trials, and female sexual dysfunction research is especially sparse. The specific gaps for bremelanotide in 2025 include:

• No published registry data with more than 12 months of follow-up
• No randomized trial in perimenopausal women with intact estrogen
• No trial in women with PCOS as the primary diagnosis
• No pharmacokinetic study in women with hepatic or severe renal impairment (the label excludes these populations by default)
• No trial comparing bremelanotide plus sex therapy versus sex therapy alone vs. Drug alone, despite evidence that combination approaches outperform monotherapy in HSDD
• No long-term (beyond 52 weeks) safety data in any population
• No data specifically in Black, Latina, or Asian women, despite the melanocortin pathway's known interaction with skin pigmentation making these populations particularly relevant for hyperpigmentation risk

The RECONNECT trial population was 78% non-Hispanic white, which limits the generalizability of both efficacy and safety findings. This is an honest limitation any prescriber should name when counseling a patient.